Phase 1 INCA035784 bispecific mAb targeting CALRmut and CD3 in MPN

This Phase 1 open-label study of INCA035784—a bispecific antibody targeting CALR-mutant and CD3—is evaluating safety, tolerability, and optimal dosing in patients with myeloproliferative neoplasms, including myelofibrosis and essential thrombocythemia with CALR exon-9 mutations. The trial features a dose-escalation phase followed by dose expansion in first-in-human research conducted by Incyte Corporation.